Since the human and rat immune systems demonstrate comparable FcεR expression and cellular distribution, the efficacy and safety of IgE antibodies, including of the first-in-class IgE, MOv18, have been studied in fully immunocompetent syngeneic rat models of cancer [20, 24, 32]. This evidence concerns the gene IGHE and cancer.